Medico Remedies Ltd
Incorporated in 1994, Medico Remedies Ltd manufactures and sells pharmaceutical formulations[1]
- Market Cap ₹ 402 Cr.
- Current Price ₹ 48.4
- High / Low ₹ 101 / 44.5
- Stock P/E 57.6
- Book Value ₹ 5.74
- Dividend Yield 0.00 %
- ROCE 21.1 %
- ROE 18.0 %
- Face Value ₹ 2.00
Pros
- Company has reduced debt.
- Company has delivered good profit growth of 42.8% CAGR over last 5 years
Cons
- Stock is trading at 8.44 times its book value
- Though the company is reporting repeated profits, it is not paying out dividend
- Company has a low return on equity of 13.8% over last 3 years.
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Sector: Pharmaceuticals Industry: Pharmaceuticals - Indian - Bulk Drugs & Formln
Quarterly Results
Figures in Rs. Crores
Profit & Loss
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | TTM | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
34 | 45 | 51 | 67 | 54 | 61 | 98 | 89 | 122 | 121 | 140 | 132 | |
32 | 43 | 48 | 63 | 50 | 58 | 95 | 86 | 117 | 114 | 131 | 120 | |
Operating Profit | 1 | 2 | 3 | 4 | 4 | 3 | 3 | 3 | 5 | 7 | 10 | 11 |
OPM % | 4% | 5% | 6% | 5% | 7% | 6% | 3% | 3% | 4% | 6% | 7% | 9% |
0 | 0 | 0 | 0 | 0 | 1 | 2 | 2 | 1 | 2 | 4 | 2 | |
Interest | 0 | 1 | 1 | 1 | 1 | 2 | 1 | 1 | 1 | 1 | 1 | 1 |
Depreciation | 0 | 1 | 1 | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 3 | 3 |
Profit before tax | 1 | 1 | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 6 | 10 | 9 |
Tax % | 40% | 34% | 28% | 40% | 4% | 35% | 28% | 26% | 30% | 26% | 28% | |
0 | 1 | 1 | 1 | 2 | 1 | 2 | 2 | 3 | 5 | 7 | 7 | |
EPS in Rs | 0.21 | 0.25 | 0.25 | 0.35 | 0.25 | 0.15 | 0.19 | 0.20 | 0.31 | 0.58 | 0.87 | 0.83 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 15% |
5 Years: | 18% |
3 Years: | 17% |
TTM: | -9% |
Compounded Profit Growth | |
---|---|
10 Years: | 33% |
5 Years: | 43% |
3 Years: | 64% |
TTM: | -5% |
Stock Price CAGR | |
---|---|
10 Years: | % |
5 Years: | 61% |
3 Years: | 113% |
1 Year: | -37% |
Return on Equity | |
---|---|
10 Years: | 10% |
5 Years: | 11% |
3 Years: | 14% |
Last Year: | 18% |
Balance Sheet
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Sep 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 1 | 1 | 2 | 2 | 3 | 4 | 4 | 4 | 4 | 17 | 17 | 17 |
Reserves | 4 | 7 | 12 | 13 | 13 | 23 | 24 | 26 | 28 | 20 | 27 | 31 |
6 | 8 | 8 | 14 | 19 | 13 | 14 | 14 | 15 | 13 | 10 | 8 | |
8 | 14 | 14 | 17 | 13 | 20 | 35 | 32 | 28 | 28 | 34 | 47 | |
Total Liabilities | 18 | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 102 |
4 | 8 | 8 | 7 | 7 | 7 | 12 | 13 | 15 | 18 | 22 | 21 | |
CWIP | 0 | 0 | 0 | 0 | 3 | 4 | 1 | 2 | 0 | 0 | 0 | 0 |
Investments | 1 | 0 | 1 | 1 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 |
14 | 23 | 27 | 38 | 39 | 48 | 63 | 60 | 59 | 59 | 66 | 81 | |
Total Assets | 18 | 31 | 36 | 46 | 48 | 59 | 76 | 75 | 76 | 77 | 87 | 102 |
Cash Flows
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|
-3 | 5 | 5 | 1 | -11 | 6 | 8 | |||||
-3 | -5 | -4 | -3 | -17 | -2 | -7 | |||||
6 | -1 | -1 | 3 | 18 | -6 | -2 | |||||
Net Cash Flow | -0 | -0 | -0 | 0 | -10 | -2 | -0 |
Ratios
Figures in Rs. Crores
Mar 2013 | Mar 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | |
---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 24 | 49 | 53 | 107 | 122 | 102 | 109 | 98 | 82 | 92 | 94 |
Inventory Days | 61 | 81 | 76 | 63 | 96 | 125 | 74 | 99 | 58 | 76 | 69 |
Days Payable | 89 | 139 | 122 | 106 | 112 | 147 | 149 | 143 | 100 | 113 | 108 |
Cash Conversion Cycle | -4 | -10 | 6 | 64 | 105 | 80 | 33 | 54 | 39 | 54 | 54 |
Working Capital Days | 69 | 68 | 77 | 109 | 163 | 146 | 87 | 90 | 80 | 82 | 76 |
ROCE % | 11% | 10% | 11% | 10% | 9% | 8% | 8% | 10% | 15% | 21% |
Documents
Announcements
- Certificate Under Regulation 40(9) Of SEBI (Listing Obligations And Disclosure Requirements) Regulations, 2015 For The Year Ended 31St March, 2024 5h
- Compliance Certificate For The Year Ended On 31St March, 2024 Pursuant To Regulation 7(3) Of The SEBI (LODR) Regulations, 2015 2d
- Closure of Trading Window 27 Mar
-
Clarification sought from Medico Remedies Ltd
22 Mar - Exchange has sought clarification from Medico Remedies Ltd on March 22, 2024 with reference to significant movement in price, in order to ensure that investors …
-
Announcement under Regulation 30 (LODR)-Newspaper Publication
14 Feb - Newspaper advertisement pursuant to Regulation 47 of LODR Regulations, 2015 for unaudited results of quarter ended 31st December, 2023.
Business Overview:[1][2]
MRL is a pharmaceutical formulation manufacturing and marketing company with focus on antibiotic, anti-infective, beta-lactam penicillin, cephalosporin, anti fungal, antimalarial, antiretroviral, anti-ulcer drugs and antacids, vitamins & supplements, hematinic and other drugs viz. NSAIDS, antihistaminic, anti-diabetics, cardiovascular drugs, antipyretic, analgesic, diuretics, anti-epileptics, antidepressants, antipsychotics, combination drug kits, dry syrups, ointments and cream & gel for various therapeutic segments